{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:02:14Z","timestamp":1776258134510,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12185-025-04127-5","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:28:07Z","timestamp":1764754087000},"page":"570-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of elranatamab in relapsed\/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-7756","authenticated-orcid":false,"given":"Taku","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukyo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Nomura-Yogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Kunisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"4127_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. Locommotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"4127_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"4127_CR3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136.","journal-title":"Nat Med"},{"key":"4127_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665\u201375.","journal-title":"J Clin Oncol"},{"key":"4127_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care Ciltacabtagene Autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"4127_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","volume":"14","author":"F Malard","year":"2024","unstructured":"Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M, et al. Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 2024;14:219.","journal-title":"Blood Cancer J"},{"key":"4127_CR7","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"4127_CR8","doi-asserted-by":"publisher","first-page":"e3302","DOI":"10.1002\/hon.3302","volume":"42","author":"T Kikuchi","year":"2024","unstructured":"Kikuchi T, Oda Y, Kondo U, Tsukada N, Kunisada K, Matsumoto C, et al. Prognostic value of the \u2018dynamic\u2019 R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies. Hematol Oncol. 2024;42:e3302.","journal-title":"Hematol Oncol"},{"key":"4127_CR9","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"4127_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4127_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00262-024-03711-8","volume":"73","author":"Y Shimazu","year":"2024","unstructured":"Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, et al. The lymphocyte\/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer Immunol Immunother. 2024;73:135.","journal-title":"Cancer Immunol Immunother"},{"key":"4127_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41408-025-01314-9","volume":"15","author":"D Dima","year":"2025","unstructured":"Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, et al. Outcomes of teclistamab in patients with relapsed\/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. multiple myeloma immunotherapy consortium. Blood Cancer J. 2025;15:111.","journal-title":"Blood Cancer J"},{"key":"4127_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35.","journal-title":"Blood Cancer J"},{"key":"4127_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371.","journal-title":"Leukemia"},{"key":"4127_CR15","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere. 2024;8:e136.","journal-title":"Hemasphere"},{"key":"4127_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2022008021","volume":"7","author":"CV Edwards","year":"2023","unstructured":"Edwards CV, Hassan H, Yildirim C, Ferri G, Verma KP, Murray Horwitz ME, et al. Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023;7:482\u201390.","journal-title":"Blood Adv"},{"key":"4127_CR17","doi-asserted-by":"publisher","first-page":"204062072211424","DOI":"10.1177\/20406207221142487","volume":"13","author":"Y Shimazu","year":"2022","unstructured":"Shimazu Y, Kanda J, Kaneko H, Imada K, Yamamura R, Kosugi S, et al. Monocyte or white blood cell counts and \u03b2(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide. Ther Adv Hematol. 2022;13:20406207221142490.","journal-title":"Ther Adv Hematol"},{"key":"4127_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12185-021-03201-y","volume":"114","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Nishiwaki K, Nagao R, Katori M, Fukushima R, Hattori D, et al. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis. Int J Hematol. 2021;114:599\u2013607.","journal-title":"Int J Hematol"},{"key":"4127_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615\u201328.","journal-title":"Blood"},{"key":"4127_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1178331","volume":"327","author":"F Geissmann","year":"2010","unstructured":"Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656.","journal-title":"Science"},{"key":"4127_CR21","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1038\/bcj.2017.60","volume":"7","author":"T Dosani","year":"2017","unstructured":"Dosani T, Covut F, Beck R, Driscoll JJ, de Lima M, Malek E. Significance of the absolute lymphocyte\/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7:e579.","journal-title":"Blood Cancer J"},{"key":"4127_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an international myeloma working group study. Blood Cancer J. 2025;15:53.","journal-title":"Blood Cancer J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04127-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:56:46Z","timestamp":1776254206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04127-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4127"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04127-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TK received personal fees from Janssen Pharmaceuticals (Titusville, NJ, USA), Takeda (Osaka, Japan), Bristol-Myers Squibb (New York, NY, USA), Pfizer (New York, NY, USA), and Sanofi (Paris, France). NT received personal fees from Janssen and Sanofi. TI received honoraria from Ono Pharmaceutical Co., Ltd. (Osaka, Japan), Takeda, Celgene\/Bristol-Myers Squibb, and Janssen. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Japanese Red Cross Medical Center (JRCMC; Tokyo, Japan) and was conducted under an abbreviated informed consent procedure and an opt-out consent principle. No participants were excluded from the study. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}